Cargando…

The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab

Detalles Bibliográficos
Autores principales:	Lieb, Sabine, Ebel, Sebastian, Seehofer, Daniel, Berg, Thomas, van Bömmel, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944522/ https://www.ncbi.nlm.nih.gov/pubmed/36860264 http://dx.doi.org/10.21037/hbsn-22-280

Ejemplares similares

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
por: Sinner, Friedrich, et al.
Publicado: (2022)

Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis
por: Yang, Ming, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
por: Krug, Sebastian, et al.
Publicado: (2021)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
por: AL Zahrani, Ali, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2023)

Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
por: Tsuruoka, Mio, et al.
Publicado: (2022)

Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy
por: Hu, Ze-Xin, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma
por: Zhang, D.X.
Publicado: (2020)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Kudo, Masatoshi
Publicado: (2021)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
por: Zhu, Andrew X., et al.
Publicado: (2022)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2022)

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2023)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
por: Takeuchi, Yasuto, et al.
Publicado: (2023)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
por: Rimini, M., et al.
Publicado: (2022)

Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas
por: Olbrich, Anne, et al.
Publicado: (2022)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ejkh2ubfm53ut7nvad57gkk44f